OptimizeRx (OPRX) Expected to Announce Quarterly Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX) is anticipated to issue its quarterly earnings data after the market closes on Wednesday, March 26th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $30.36 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

OptimizeRx Stock Performance

Shares of NASDAQ:OPRX opened at $8.63 on Monday. The firm has a 50 day moving average of $5.84 and a 200 day moving average of $5.92. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $158.97 million, a price-to-earnings ratio of -6.49 and a beta of 1.31. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $14.13.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Lake Street Capital reaffirmed a “buy” rating and set a $11.00 price objective on shares of OptimizeRx in a research report on Tuesday, December 24th. Stephens assumed coverage on shares of OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 price objective for the company. Royal Bank of Canada restated a “sector perform” rating and issued a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. B. Riley upgraded OptimizeRx to a “strong-buy” rating in a report on Wednesday, March 12th. Finally, JMP Securities restated a “market outperform” rating and set a $8.00 target price on shares of OptimizeRx in a research note on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.06.

Insider Buying and Selling

In related news, Director James Paul Lang acquired 321,408 shares of OptimizeRx stock in a transaction on Friday, March 14th. The stock was acquired at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the purchase, the director now owns 389,452 shares of the company’s stock, valued at approximately $2,959,835.20. This represents a 472.35 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.10% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.